Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
16,121 stopped studies · 89% state a reason
Over the 16,121 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT06779669 | Use of Alternative and Complementary Medicine by Colorectal Cancer Patients(ALTERNATIVCCR) | N/A | terminated | Jan 16, 2025 | University Hospital, Limoges | Not enough awnser in the qualitative study | Other (stated, no rule matched) |
| NCT06963216 | A Study Investigating Coagadex in the Treatment AFXD Associated With AL Amyloidosis | Phase 3 | withdrawn | May 8, 2025 | Kedrion S.p.A. | Study was discontinued for non-safety reasons and the rapidly evolving treatment landscape for AL… | Safety / toxicity |
| NCT03436745 | The Effects of Castration on the Pharmacokinetics of Zolpidem After Single Dose… | Phase 1 | terminated | Feb 19, 2018 | National Cancer Institute (NCI) | Slow/insufficient accrual | Enrollment / accrual |
| NCT05255601 | A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of…(RELATIVITY-069) | Phase 1 / Phase 2 | terminated | Feb 24, 2022 | Bristol-Myers Squibb | not stated | Not stated |
| NCT05578274 | Abscopal Effect From Low-dose Radiotherapy in Metastatic Cancer Combined With… | N/A | withdrawn | Oct 13, 2022 | Soonchunhyang University Hospital | insufficient participant enrollment | Enrollment / accrual |
| NCT05999968 | Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial Treatment | Phase 1 | terminated | Aug 21, 2023 | Eli Lilly and Company | The study was terminated early as related study I3Y-MC-JPCM (NCT03706365) did not meet its primary… | Other (stated, no rule matched) |
| NCT06068543 | Reducing Frailty for Older Cancer Survivors Using Supplements II(ReFOCUS2) | Phase 2 | suspended | Oct 5, 2023 | University of Rochester | The study has been suspended by the IRB pending review of a study-related issue | Other (stated, no rule matched) |
| NCT07146113 | Treatment Approaches and Biomarkers PRevalence In de Novo MEtastatic Hormone-sensitive…(PRIME) | — | suspended | Aug 28, 2025 | AstraZeneca | As a part of planned reassessment for the current period, a decision has been made to prioritize,… | Enrollment / accrual |
| NCT03139058 | Prevalence of Liver Fibrosis and Cirrhosis in Patients With Squamous Cell Carcinoma of…(fibr'HOM) | N/A | terminated | May 3, 2017 | Centre Hospitalier Universitaire, Amiens | Recruitment difficulties | Enrollment / accrual |
| NCT04251715 | mFOLFIRINOX Followed by Hepatic Arterial Infusion of Floxuridine and Dexamethasone With… | Phase 2 | terminated | Feb 5, 2020 | OHSU Knight Cancer Institute | change in standard-of-care systemic therapy | Other (stated, no rule matched) |
| NCT05050162 | Comparing Cisplatin Every Three Weeks to Cisplatin Weekly When Combined With Radiation… | Phase 2 / Phase 3 | suspended | Sep 20, 2021 | NRG Oncology | End of Initial Phase of Multi-phase protocol; closed for protocol specified analysis | Other (stated, no rule matched) |
| NCT05207709 | Ribociclib vs. Palbociclib in Patients With Advanced Breast Cancer Within the…(HARMONIA) | Phase 3 | terminated | Jan 26, 2022 | SOLTI Breast Cancer Research Group | The study was prematurely halted because enrollment was significantly delayed compared with the… | Enrollment / accrual |
| NCT05712694 | Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With… | Phase 3 | terminated | Feb 3, 2023 | Polaris Group | Lack of Efficacy, no safety concern. | Safety / toxicity |
| NCT05716009 | Tagraxofusp-erzs, an IL-3 Diphtheria Fusion Protein, in Combination With Gemtuzumab…(GO-TAG) | Phase 1 | terminated | Feb 8, 2023 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Upon analysis of the first 7 participants accrued, it was determined that this combination… | Enrollment / accrual |
| NCT07100925 | A Study of Tolododekin Alfa (ANK-101) in Renal Allograft Recipients With High Risk… | Phase 1 | withdrawn | Aug 3, 2025 | Ankyra Therapeutics, Inc | Strategic realignment | Sponsor / business decision |
| NCT07136493 | Circulating Tumor DNA Based Minimal Residual Disease Detection for Patients With… | N/A | withdrawn | Aug 22, 2025 | City of Hope Medical Center | Funding This study has been closed at City of Hope at the request of the Sponsor due to delays and… | Funding |
| NCT01012297 | Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients… | Phase 3 | terminated | Nov 13, 2009 | National Cancer Institute (NCI) | The study was targeted to accrue 130 patients, but closed early for futility. | Efficacy / futility |
| NCT02104011 | Treatment of Renal Angiomyolipomas in Tuberous Sclerosis by Beta-blockers(STBETA) | Phase 2 | terminated | Apr 4, 2014 | University Hospital, Bordeaux | target number of subject not reached | Other (stated, no rule matched) |
| NCT02577094 | Testing a Reduced Conditioning Regimen FB2A2 Preceded by a Fractionated…(EPRALLO) | Phase 1 / Phase 2 | withdrawn | Oct 16, 2015 | Nantes University Hospital | not stated | Not stated |
| NCT03630640 | Neoadjuvant and Adjuvant Nivolumab in HCC Patients Treated by Electroporation(NIVOLEP) | Phase 2 | terminated | Aug 15, 2018 | Assistance Publique - Hôpitaux de Paris | Because patient recruitment was affected by the COVID-19 pandemic, the study sponsor and funding… | COVID-19 / pandemic |
| NCT05416554 | Long-term Cognitive, Neuropsychiatric and Functional Outcomes in Adults Who Have Received… | N/A | withdrawn | Jun 13, 2022 | Stanford University | No participants enrolled | Enrollment / accrual |
| NCT06378918 | Comparison of the Effectiveness of the Simple Puncture Compared to the Incision of an…(PILO) | N/A | terminated | Apr 23, 2024 | University Hospital, Angers | change of care at the center and low recruitment rate | Enrollment / accrual |
| NCT06692959 | A Phase II Trial of Neoadjuvant PD-1 Vaccine PD1-Vaxx in Operable MSI High Colorectal…(Neo-POLEM) | Phase 2 | terminated | Nov 18, 2024 | University of Southampton | funding withdrawal | Funding |
| NCT06869278 | A Study of LCAR-AIO CAR-T Cells for Treating Relapsed/Refractory Neurological Autoimmune… | Phase 1 | withdrawn | Mar 11, 2025 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Legend discontinues the development of the IMP. | Other (stated, no rule matched) |
| NCT00520975 | Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses… | Phase 3 | terminated | Aug 27, 2007 | National Cancer Institute (NCI) | Closed early due to slow accrual | Enrollment / accrual |
| NCT03353428 | Intervention of Engineered Immune Effector T Cells Against Lung Cancer | Phase 1 / Phase 2 | withdrawn | Nov 27, 2017 | Shenzhen Geno-Immune Medical Institute | combine with NCT03356808 | Other (stated, no rule matched) |
| NCT04346225 | Magnetic Resonance Imaging (MRI) With Hyperpolarized Pyruvate (13C) as Diagnostic Tool in… | Phase 2 | suspended | Apr 15, 2020 | Ivan de Kouchkovsky, MD | Due to funding | Funding |
| NCT04734704 | Defining the Role of the Skin Microbiome in Immune-related Adverse Events(SKINBIOTA) | N/A | terminated | Feb 2, 2021 | University Hospital, Bordeaux | target number of patients not reached and disabling team changes | Other (stated, no rule matched) |
| NCT05109975 | A Study to Evaluate Safety and Preliminary Anti-tumor Activity of Debio 0123 as… | Phase 1 | terminated | Nov 5, 2021 | Debiopharm International SA | This trial was concluded for strategic reasons. | Sponsor / business decision |
| NCT06076837 | The Seven Trial: Exploiting the Unfolded Protein Response | Phase 1 | terminated | Oct 11, 2023 | HonorHealth Research Institute | The study was terminated early per the recommendation of the Data and Safety Monitoring Board… | Safety / toxicity |
| NCT07399990 | Efficacy of Superoxide Dismutase in Preventing Radiation Dermatitis in Patients With Head… | N/A | withdrawn | Feb 10, 2026 | West China Hospital | This study was withdrawn prior to enrollment due to administrative error in the registration… | Enrollment / accrual |
| NCT07400016 | Efficacy of Superoxide Dismutase Spray in Preventing Radiation Dermatitis in Patients… | N/A | withdrawn | Feb 10, 2026 | West China Hospital | This study was withdrawn prior to enrollment due to administrative error in the registration… | Enrollment / accrual |
| NCT04581109 | Detection of Viable CTCs Using the EPIDROP Technology in Metastatic Prostate Cancer…(EPIDROP) | N/A | terminated | Oct 9, 2020 | University Hospital, Montpellier | Flaw in the analytical technique | Other (stated, no rule matched) |
| NCT05025514 | Retrospective Study of COVID-19 Vaccines in Patients Undergoing Immunotherapy for Cancer.(IVACOV) | — | terminated | Aug 27, 2021 | Centre Hospitalier Universitaire de Nīmes | end of the COVID outbreak | COVID-19 / pandemic |
| NCT05315011 | Assessment of Cryotherapy's Analgesic Impact in Anti-aromatase-induced Arthralgia(CRYOMATASE) | N/A | suspended | Apr 7, 2022 | University Hospital, Montpellier | The cryotherapy center has closed due to liquidation. | Other (stated, no rule matched) |
| NCT05325866 | A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor…(FORTITUDE-301) | Phase 1 / Phase 2 | terminated | Apr 13, 2022 | Amgen | Sponsor Decision | Sponsor / business decision |
| NCT05350527 | Impact of Video Information Support on Preoperative Anxiety in Breast Cancer Surgery(SENEDOP) | N/A | terminated | Apr 28, 2022 | University Hospital, Montpellier | The software used for the collection of the primary endpoint is no longer available. | Other (stated, no rule matched) |
| NCT07050836 | Contrast Enhanced Ultrasound in Neurosurgery to Improve Glioma Visualization and Border… | Early Phase 1 | terminated | Jul 3, 2025 | University of Colorado, Denver | Per Principal Investigator decision. | Investigator |
| NCT07216833 | Decitabine and Nivolumab in Participants With Recurrent/Metastatic Squamous Cell… | Phase 1 | withdrawn | Oct 15, 2025 | Case Comprehensive Cancer Center | PI leaving the institution | Other (stated, no rule matched) |
| NCT07524257 | Phase 3 Study of Nogapendekin Alfa Inbakicept Plus Standard of Care vs Standard of Care… | Phase 3 | withdrawn | Apr 13, 2026 | ImmunityBio, Inc. | Sponsor decision | Sponsor / business decision |
| NCT07570966 | Study of ERW316 as a Single Agent or in Combination With Endocrine Therapy in Patients… | Phase 1 / Phase 2 | withdrawn | May 6, 2026 | Novartis Pharmaceuticals | Business decision | Sponsor / business decision |
| NCT00253318 | RAD001 Plus Docetaxel in Patients With Metastatic Breast Cancer | Phase 1 | terminated | Nov 15, 2005 | M.D. Anderson Cancer Center | Toxicity and Lack of Efficacy | Safety / toxicity |
| NCT02389985 | A Study of CRLX101(NLG207) in Combination With Weekly Paclitaxel in Patients With… | Phase 1 / Phase 2 | terminated | Mar 17, 2015 | NewLink Genetics Corporation | Company decision | Sponsor / business decision |
| NCT04702854 | Evaluation of Ultrasound Biomicroscopy in the Local Staging of Cutaneous Melanoma(BMUMM) | N/A | terminated | Jan 11, 2021 | Centre Hospitalier Universitaire de Nice | recruitment challenges | Enrollment / accrual |
| NCT04975516 | Standard of Care Chemotherapy With or Without Stereotactic Body Radiation Therapy for… | Phase 2 | terminated | Jul 23, 2021 | Mayo Clinic | Low/slow accrual | Enrollment / accrual |
| NCT05130255 | GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2 | Phase 1 | terminated | Nov 23, 2021 | Y-mAbs Therapeutics | Decision by Sponsor | Other (stated, no rule matched) |
| NCT05514717 | A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2 | Phase 1 | terminated | Aug 24, 2022 | Day One Biopharmaceuticals, Inc. | Development discontinued. | Other (stated, no rule matched) |
| NCT05537402 | LOcoregional vs Systemic Therapy in Patients With BCLC Stage B HCC(LOST-B) | Phase 2 | terminated | Sep 13, 2022 | University of Texas Southwestern Medical Center | The decision was made to close the study to enrollment due to poor overall accrual and the… | Enrollment / accrual |
| NCT06035744 | CLN-617 Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors | Phase 1 | terminated | Sep 13, 2023 | Cullinan Therapeutics Inc. | Company decision | Sponsor / business decision |
| NCT06274437 | A Study of BND-35 in Participants With Advanced Solid Tumors | Phase 1 | terminated | Feb 23, 2024 | Biond Biologics | Study terminated due to strategic considerations | Sponsor / business decision |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Jun 29, 2026source: clinicaltrials